Goldman's optimistic view of Alzheimer's drug lifts Biogen shares

17 August 2017

Goldman Sachs (NYSE: GS) cited Biogen’s (Nasdaq: BIIB) experimental Alzheimer’s drug aducanumab as a major reason for its addition of the US biotech company to the investment bank’s Equity Conviction List.

This is effectively a strong recommendation to investors to buy stock, and markets reacted to the news, issued in a research note by Goldman Sachs analysts, by sending Biogen shares up 2% in Wednesday’s trading, to a closing price of $294.08.

The analysts noted that, based on their expectation for late-stage data on aducanumab in late 2019 or 2020, it could be one of the first disease-modifying drugs to reach the multi-billion dollar Alzheimer’s market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK